Follow The Filings

KALA KALA BIO

KALA BIO earnings company data as of 4:49 AM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

2 periods, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 18 Nov EPS — — —
Rev — — —
FY2026 Q2 21 Aug EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by KALA's executives, directors and 10% owners in the last 12 months, from their Form 4s

All KALA insider trades
  • None no insider bought on the open market
  • $126K sold by 2 insiders outside a trading plan
  • None no planned (10b5-1) sales
  1. Darius Kharabi Chief Business Officer
    Sale
    $17K 20,806 shares at $0.8300 33% of stake
    Traded Oct 22, 2025 Filed Oct 24, 2025
  2. Mary Reumuth CFO
    Sale
    $28K 33,197 shares at $0.8300 54% of stake
    Traded Oct 22–23 Filed Oct 24, 2025
  3. Todd Bazemore Director
    Sale
    $40K 47,768 shares at $0.8300 57% of stake
    Traded Oct 22, 2025 Filed Oct 24, 2025
  4. Mark T Iwicki Director
    Sale
    $125K 154,894 shares at $0.8100 60% of stake
    Traded Oct 23, 2025 Filed Oct 24, 2025
  5. Romulus K Brazzell See Remarks
    Sale
    $39K 46,748 shares at $0.8300 57% of stake
    Traded Oct 22, 2025 Filed Oct 24, 2025

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
SCHEDULE 13G —
DEF 14A
8-K 1.01,9.01
8-K 5.08,8.01
8-K 3.01
10-Q
8-K 8.01,9.01
424B5
SCHEDULE 13D/A —
SCHEDULE 13G/A —
10-Q
8-K 3.03,5.03,8.01,9.01
10-K
8-K 1.01,3.02,7.01
8-K 5.02
SCHEDULE 13G/A —
424B3
SCHEDULE 13D —
8-K 5.02
8-K 1.01,3.02,5.01,5.02,5.03,5.07,9.01
DEFA14A
8-K 3.01
SCHEDULE 13G —
424B5
8-K 1.01,9.01

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.